BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15156609)

  • 1. Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C.
    Kryczka W; Zarebska-Michaluk D; Chrapek M
    Med Sci Monit; 2003 Aug; 9 Suppl 3():32-5. PubMed ID: 15156609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon.
    Diago M; Luján M; Valeros D; Tuset C; Marcaida G; García V; Cors R; Carbonell P
    Rev Esp Enferm Dig; 2001 Jun; 93(6):353-63. PubMed ID: 11482039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
    Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
    Hofer H; Osterreicher C; Jessner W; Penz M; Steindl-Munda P; Wrba F; Ferenci P
    J Hepatol; 2004 Jun; 40(6):1018-22. PubMed ID: 15158344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of HCV RNA in hepatic tissue and effectiveness of treatment with interferon and ribavirin.
    Lakomy EA; Bielawski KP; Sikorska K; Stalke P; Michalska Z; Witczak-Malinowska K
    Med Sci Monit; 2003 Aug; 9 Suppl 3():36-8. PubMed ID: 15156610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C in hemophilic patients.
    Husa P; Smejkal P; Husová L; Penka M
    Acta Virol; 2004; 48(1):35-8. PubMed ID: 15230473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
    Yu ML; Dai CY; Lee LP; Hou NJ; Hsieh MY; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Liver Int; 2006 Dec; 26(10):1187-95. PubMed ID: 17105583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Tanioka D; Iwasaki Y; Araki Y; Osawa T; Ikeda H; Ando M; Kobashi H; Sakaguchi K; Shiratori Y; Yamamoto K
    Liver Int; 2009 May; 29(5):721-9. PubMed ID: 19141025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retreatment of patients with chronic hepatitis C].
    Ostojić R
    Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2005 Aug; 67(2):93-7. PubMed ID: 16051377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Lin ZY; Hou NJ; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2004 Oct; 64(1):47-53. PubMed ID: 15451178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.